



CODEN [USA]: IAJPBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<https://zenodo.org/records/10981396>Available online at: <http://www.iajps.com>

Review Article

**A REVIEW ON PREPARATION OF DRUG MASTER FILE FOR
REGULATORY APPROVALS**

Tadiboina Uma Maheswari*, Adilakshmi Challa, M. V. Nagabhushanam, Bolimoni
Lakshmi Sravani, Yarramsetty Naga Pavani, G Ramakrishna,
Department of Pharmaceutical Regulatory Affairs, Hindu College of Pharmacy,
Amaravathi Road, Guntur, Andhra Pradesh, India-522002.

Article Received: February 2024**Accepted: March 2024****Published: April 2024****Abstract:**

A drug master file (DMF) is a confidential, detailed document submitted by Active Pharmaceutical Ingredient (API) manufacturers to the U.S. Food and Drug Administration (FDA). A DMF contains the chemistry, manufacturing, and controls of a drug component. A drug master file is filed when two or more firms work in partnership on developing or manufacturing a drug product. The DMF filing allows a firm to protect its intellectual property from its partner while complying with regulatory requirements for disclosure of processing details. The DMF contains factual and complete information on a drug product's chemistry, manufacture, stability, purity, impurity profile, packaging, and the cGMP status of any human drug product. The pharmaceutical industry is one of the most regulated industries; no drug would be marketed without the teams of medical researchers and other specialists who worked to make sure it receives regulatory authority's approval. There is no legal or regulatory requirement to file a DMF. This study gives the information on regulatory requirements of Drug Master Files by Food and Drug Administration (USA), European Medicines Agency (Europe), Ministry of Health Labor and Welfare (Japan), Central Drug and Standard Control Organization (India) and WHO and their comparison.

Keywords: DMF, intellectual property, regulatory authority, FDA, WHO.

Corresponding author:**Tadiboina Uma Maheswari,**

IV/IV B. Pharmacy, Department of Pharmaceutical Regulatory Affairs,
Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh,
India-522002.

QR code



Please cite this article in press *Tadiboina Uma Maheswari et al, A Review On Preparation Of drug Master File For Regulatory Approvals., Indo Am. J. P. Sci, 2024; 11 (4).*

INTRODUCTION: [1-4]

A Drug Master File (DMF) is an accommodation to the Food and Drug Administration (FDA) that might be utilized to give secret definite data about offices, cycles, or articles utilized in the assembling, handling, bundling, and putting away of at least one human medications.

- The accommodation of a DMF isn't legally necessary or FDA guideline and a DMF is submitted exclusively at the caution of the holder (an individual who claims a DMF).
- The data contained in the DMF might be utilized to help an Investigational New Drug Application (IND), a New Drug Application (NDA), an Abbreviated New Drug Application (ANDA), another DMF, an Export Application, or corrections and enhancements to any of these.
- However, a DMF is definitely not a substitute for an IND, NDA, ANDA, or Export Application.

For the reasons for this rule, the accompanying definitions apply:

II.1. Organization implies the Food and Drug Administration.

II.2 Agent or delegate implies any individual who is named by a DMF holder to act as the contact for the holder.

II.3. Candidate implies any individual who presents an application or curtailed application or an alteration or supplement to them to acquire FDA endorsement of another medication or an anti-infection drug and whatever other individual who claims a supported application (21 CFR 314.3 (b)).

II.4. Drug item implies a completed measurements structure, for instance, tablet, case, or arrangement, that contains a medication substance, by and large, yet not really, in relationship with at least one different fixings (21 CFR 314.3 (b)).

II.5. Drug substance implies a functioning fixing that is expected to outfit pharmacological action or other direct impact in the analysis, fix, relief, treatment, or counteraction of infection or to influence the design or any capacity of the human body, however does exclude intermediates utilized in the union of such fixing (21 CFR 314.3 (b)).

II.6. Send out application implies an application submitted under area 802 of the Federal Food, Drug, and Cosmetic Act to trade a medication that isn't endorsed for promoting in the United States.

II.7. Holder implies an individual who possesses a DMF.

II.8. Letter of approval implies a composed assertion by the holder or assigned specialist or delegate

allowing FDA to allude to data in the DMF on the side of someone else's accommodation.

II.9. Individual incorporates individual, organization, enterprise, and affiliation. (Segment 201(e) of the Federal Food, Drug, and Cosmetic Act.)

II.10. Support implies an individual who takes more time for and starts a clinical examination. The support might be an individual or drug organization, administrative office, scholastic foundation, private association, or other association.

Drug Master Files are accommodated in 21 CFR 314.420.

- This rule is expected to furnish DMF holders with techniques satisfactory to the office for getting ready and presenting a DMF.
- The rule examines kinds of DRUG MASTER FILE, the data required in each sort, the organization of entries to a DMF, the regulatory methods administering audit of DRUG MASTER FILE, and the commitments of the DMF holder.
- DRUG MASTER FILE are by and large made to permit a party other than the holder of the DMF to reference material without revealing to that party the items in the record.
- Whenever a candidate references its own material, the candidate ought to reference the data contained in its own IND, NDA, or ANDA straightforwardly instead of laying out another DMF.

SUBMISSIONS TO DRUG MASTER FILES [5-7]

Each DMF submission ought to contain a conveyance letter, managerial data about the submission, and the particular data to be remembered for the DMF as portrayed in this segment.

The DMF should be in the English language. Whenever a submission contains data in another dialect, a precise affirmed English interpretation should likewise be incorporated.

Each page of each duplicate of the DMF ought to be dated and sequentially numbered. A refreshed list of chapters ought to be incorporated with every submission.

A. Transmitting Letters:

The accompanying ought to be incorporated:

A.1. Unique Submissions

a. ID of submission: Original, the sort of DMF as characterized in Section III, and its subject.

b. ID of the applications, whenever known, that the DMF is planned to help, including the name and

address of each support, candidate, or holder, and all significant report numbers.

c. Mark of the holder or the approved agent.

d. Typewritten name and title of the underwriter.

A. 2. Amendments

a. Distinguishing proof of submission: Amendment, the DMF number, kind of DMF, and the subject of the change.

b. A portrayal of the reason for submission, e.g., update, overhauled equation, or amended process.

c. Mark of the holder or the approved agent.

d. Typewritten name and title of the underwriter.

B. Administrative Information

Administrative information should include the following:

B.1. Unique Submissions

a. Names and addresses of the accompanying:

(1) DMF holder.

(2) Corporate base camp.

(3) Manufacturing/handling office.

(4) Contact for FDA correspondence.

(5) Agent(s), if any.

b. The particular obligations of every individual recorded in any of the classes in Section a.

c. Proclamation of responsibility.

A marked assertion by the holder affirming that the DMF is current and that the DMF holder will follow the assertions made in it.

B2. Revisions

a. Name of DMF holder.

b. DMF number.

c. Name and address for correspondence.

d. Impacted segment as well as page quantities of the DMF.

e. The name and address of every individual whose IND, NDA, ANDA, DMF, or Export Application depends regarding the matter of the revision for help.

f. The quantity of each IND, NDA, ANDA, DMF, and Export Application that depends regarding the matter of the revision for help, whenever known.

g. Specific things inside the IND, NDA, ANDA, DMF, and Export Application that are impacted, whenever known.

C. Drug Master File Contents:

C.1. Types of Drug master file

Types essential contents:

I Manufacturing site, offices, working system and staff

II Drug substance and transitional, material utilized and drug item

III Packaging material

IV Excipient, flavor, substance, colorant, and material utilized in readiness

V FDA acknowledged reference data

Type I: Manufacturing Site, Facilities, Operating Procedures, and Personnel.

A Type I DMF is suggested for an individual outside of the United States to help FDA in directing nearby reviews of their assembling offices. The DMF ought to depict the assembling site, hardware capacities, and functional format. A Type I DMF is regularly not expected to depict homegrown offices, besides in exceptional cases, for example, when an individual isn't enrolled and not regularly assessed. The portrayal of the site ought to incorporate genuine site address, and a guide showing its area as for the closest city. An ethereal photo and a chart of the site might be useful. An outline of significant creation and handling regions is useful for getting the functional format. Significant hardware ought to be depicted regarding abilities, application, and area. Make and model wouldn't typically be required except if the hardware is new or one of a kind. An outline of major corporate hierarchical components, with key assembling, quality control, and quality affirmation positions featured, at both the assembling site and corporate base camp, is likewise useful.

Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product

A Type II DMF ought to, as a rule, be restricted to a solitary medication middle of the road, drug substance, drug item, or kind of material utilized in their planning. (1) Drug Substance Intermediates, Drug Substances, and Material Used in Their Preparation. Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. Rule for the Format and Content of the Chemistry, Manufacturing, and Controls Section of an Application. (2) Drug Product Guideline for the Format and Content of the Chemistry, Manufacturing, and Controls Section of an Application. Rule for Submitting Documentation for the Manufacture of and Controls for Drug Products. Rule for Submitting Samples and Analytical Data for Methods Validation

Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation

- Every added substance ought to be recognized and described by its technique for make, discharge particulars, and testing strategies.
- Toxicological information on these materials would be incorporated under this kind of DMF, while possibly not in any case accessible by cross reference to another record.

- Usually, the authority compendia and FDA guidelines for variety added substances (21 CFR Parts 70 through 82), direct food added substances (21 CFR Parts 170 through 173), circuitous food added substances (21 CFR Parts 174 through 178), and food substances (21 CFR Parts 181 through 186) might be utilized as hotspots for discharge tests, particulars, and security.
- Guidelines recommended for a Type II DMF might be useful for setting up a Type IV DMF

Type V: FDA acknowledged Reference Information

- FDA beats the utilization of Type V DMF's for incidental data, copy data down, or data that ought to be remembered for one of different sorts of Dmf's.
- If any holder wishes to submit data and supporting information in a DMF that isn't covered by Types I through IV, a holder should initially present a letter of expectation to the Drug Master File Staff. FDA will then, at that point, contact the holder to talk about the proposed accommodation.

Environmental Assessment:

Type II, Type III, and Type IV DMF's should contain a commitment by the firm that its facilities will be operated in compliance with applicable environmental laws. If a completed environmental assessment is needed.

Stability:

Stability study design, data, interpretation, and other information should be submitted, when applicable, as outlined in the "Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics."

D. Format, Assembly, and Delivery:

D.1. An unique and copy are to be submitted for all DMF submissions.

Drug Master File holders and their representatives/delegates ought to hold a total reference duplicate that is indistinguishable from, and kept in a similar ordered control as, their submissions to FDA.


D.2. The unique and copy duplicates should be gathered, completely collected, and separately jacketed.

Every volume of a DMF ought to, by and large, be something like 2 inches thick. For multivolume submissions, number every volume. For instance, for a 3 volume submission, the volumes would be numbered 1 of 3, 2 of 3, and 3 of 3.

D.3. U.S. standard paper size (8-1/2 by 11 inches) is liked.

Paper length ought not be under 10 inches nor more than 12 inches. Be that as it may, it might infrequently be important to utilize individual pages bigger than standard paper size to introduce a story plan, blend chart, bunch recipe, or assembling directions. Those pages ought to be collapsed and mounted to permit the page to be opened for survey without dismantling the coat and refolded without harm when the volume is retired.

The office's framework for documenting DMF's accommodates get together on the left half of the page. The left edge ought to be no less than three fourths of an inch to guarantee that text isn't darkened in the attached region. The right edge ought to be something like one portion of an inch. The submitter ought to poke holes 8 1/2 inches separated in each page. See the page estimations displayed in the accompanying figure:



D.5. Delivery to FDA

US DMF Filing System [8-12]

1. Filing the DMF:

- Holder sends two duplicates of the DMF to FDA
- DMF is explored for authoritative purposes simply by Central Document Room staff.
- DMF went into data set, relegated a number and affirmation letter shipped off holder
- A DMF is neither endorsed or objected

2. Getting to the DMF: Authorization (LOA):

The DMF will be assessed just when it is referred to in an Application or another DMF

- The Holder should present a two duplicates of the LOA to the DMF, in addition to a duplicate to the Applicant.
- The Applicant presents a duplicate of the LOA in their Application.
- The LOA is the main component to set off an audit of the DMF by the FDA.

3. DMF Review Procedure:

- The DMF is looked into provided that referred to by an Applicant or another DMF

- Assuming the commentator observes lacks in the DMF, the inadequacies are itemized in a letter to the Holder.
- The Applicant will be informed that lacks exist, yet the idea of the inadequacies isn't conveyed to the Applicant.

4. Format, Font, Font Size and Paper utilized for accommodation to USFDA, whether DMF gets endorsed or dismissed by USFDA

- Electronic DMF ought to be recorded. In Common Technical Document, the showcase of data ought to be unambiguous and straightforward, to work with the audit of the essential information and to assist a commentator with turning out to be immediately situated to the application contents.
- Text and tables ought to be arranged utilizing edges that permit the archive to be imprinted on both A4 paper (E.U. furthermore, Japan) and 8.5 x 11" paper (U.S.). The left-hand edge ought to be adequately enormous that data isn't clouded by the strategy for restricting. Text dimensions for text and tables ought to be of a style and size

that are sufficiently huge to be effectively readable, even subsequent to copying.

- Times New Roman, 12-point textual style is suggested for account text. Each page ought to be numbered, as per the granularity archive. Abbreviations and contractions ought to be characterized whenever they first are utilized in every module.
- DMF neither supported nor opposed by USFDA.
- U.S. standard paper size (8.5 by 11 inches) is liked. □ Paper length ought not be under 10 inches nor more than 12 inches. In any case, it might every so often be important to utilize individual pages bigger than standard paper size to introduce a story plan, combination outline, cluster equation, or assembling directions. Those pages ought to be collapsed and mounted to permit the page to be opened for survey without dismantling the coat and refolded without harm when the volume is retired.
- The organization's framework for documenting DMF's accommodates gathering on the left half of the page. The left edge ought to be something like three fourths of an inch to guarantee that text isn't clouded in the attached region. The right edge ought to be something like one portion of an inch. The submitter ought to poke holes 8 1/2 inches separated in each page.

Referral letters required for FDA submission:

In CTD, in Module 1 - Administrative Information, 1.4 Sub-segment manages references

Letter of Authorization (LOA): Submission by the proprietor of data, giving approval for the data to be utilized by another. An Agent Appointment Letter isn't a LOA and ought not be designated "Letter of Authorization" and ought not be submitted in Section 1.4.1.

Explanation of Right of Reference Submission by beneficiary of a Letter of Authorization with a duplicate of the LOA and articulation of right of reference. Submitted in a DMF just when another DMF is referred to. Assuming that a DMF holder references other DMFs a rundown of those DMFs can be given in this part. This isn't equivalent to the rundown of approved gatherings to be given in 1.4.3.

Rundown of approved people to join by reference: This rundown ought to be submitted in DMF yearly reports.

EUROPEAN DMF – Types&Filing System [12-14]

European DMF was laid out in 1989-1991. It was updated in 2005 and became ASMF (Active Substance Master File) after execution of Common

Technical Document (CTD) in EU. DMF is material just to dynamic substances.

The substance and the organization for DMF utilized in United States contrasts from that utilized in European Countries to get market approval (MA). The Main Objective of the EDMF is to help administrative prerequisites of a therapeutic item to demonstrate its quality, wellbeing and viability. This assists with getting a Marketing Authorization award.

The ASMF holder might have an ASMF as well as a Certificate of Suitability (CEP) gave by EDQM for a solitary dynamic substance. By and large, it anyway not adequate that the Applicant/MA holder alludes to an ASMF as well regarding a CEP for a solitary dynamic substance of a specific MAA/MAV. In situations where the CEP contains too little data (for example security) the National Competent Authorities/EMA might conclude that extra data ought to be given in the dossier. In such case it very well might be satisfactory to allude both to an ASMF and a CEP.

European DMF has been divided into 2 parts

Candidate Part (Open): Contains all the expected data including a layout of the assembling strategy.

ASM Restricted Part (Closed/Confidential): Confidential data of on the assembling of Active Pharmaceutical Ingredient.

European DMF Filing System:

The candidate's important for a DMF is given by the ASM (Active Substance Manufacturer) to the candidate straightforwardly and turns out to be essential for the application for advertising approval. Both the candidate's part and the ASM Restricted Part of the DMF are submitted to the specialists.

The fundamental goal of the Active Substance Master File (ASMF) methodology, previously known as the European Drug Master File (EDMF) technique, is to permit significant classified licensed innovation or 'skill' of the maker of the dynamic substance (ASM) to be safeguarded, while simultaneously permitting the Applicant or Marketing Authorisation (MA) holder to assume total ownership for the therapeutic item and the quality and quality control of the dynamic substance. Public Competent Authorities/EMA accordingly approach the total data that is important for an assessment of the reasonableness of the utilization of the dynamic substance in the restorative item.

The ASMF strategy can be utilized for the accompanying dynamic substances, including home

grown dynamic substances/arrangements. for example

- A. New dynamic substances
- B. Existing dynamic substances excluded from the European Pharmacopeia (Ph. Eur.) or the pharmacopeia of an EU Member State.
- C. Pharmacopeial dynamic substances remembered for the Ph. Eur. or on the other hand in the pharmacopeia of an EU Member State.

Candidate's essential for a DMF - Open part the candidate should be provided by the ASM with adequate data to have the option to take more time for an assessment of the appropriateness of the dynamic substance particular to control the nature of the substance. This regularly incorporates a concise framework of the assembling technique, data on potential debasements starting from the assembling strategy, from the segregation method (normal items) or from corruption and, where material, data on the poisonousness of explicit pollutions.

ASM Restricted Part of DMF - Closed part
Definite data on the singular strides of the assembling technique, for example, response conditions, temperature, approval and assessment information for specific basic strides of the assembling strategy, and so on and on quality control during production might contain significant ability. Such data may in this manner be provided to the specialists as it were.

CANADADMF –Types & Filing System [14-16]

Canada has 4 Types of DMFs

- Type I - Drug Substance, Drug Intermediates and materials used in their preparations
- Type II - Packaging material Type
- III - Colorants, Flavours and Other Additives
- Type IV - Dosage form.

Type I & IV have two sections:

- Sponsor's (Open)
- Restricted (closed)

CONCLUSION:

The study concludes that the drug master file is filed in support of various applications to present drug into the market. It is used to provide chemistry manufacturing and controls (CMCs) on drug substance, drug product, intermediate used in their preparations etc. There is no regulatory requirement to file the drug master file in any country. Each country in the world has different rules and regulations to file the drug master file (DMF). So there is a need of harmonization on filling of DMF in the world in future.

REFERENCES:

1. <https://www.fda.gov>
2. <https://www.pmda.go.jp>
3. <https://www.pharmaguideline.com>
4. <https://freversolutions.com>
5. <https://regulatoryaffairs.freyersolutions.com>
6. <https://www.pcisynthesis.com>
7. <https://www.ema.europa.eu>
8. https://en.wikipedia.org/wiki/Drug_Master_File
9. <https://www.fdahelp.us/drug-master-files.html>
10. <https://www.hsa.gov.sg/therapeutic-products/register/guides/drug-master-file>
11. Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in “BRICS” Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 20-39.
12. Brahmaiah Bonthagarala, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, Issue 6 volume 6, November-December 2016, 144-157.
13. Brahmaiah Bonthagarala, Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 1-19.
14. Brahmaiah Bonthagarala, Nanomedicine Clinical Use, Regulatory and Toxicology Issues in Europe, Journal of Drug Delivery and Therapeutics, 2019; 9(4-s):846-848.
15. Brahmaiah Bonthagarala, Generic Drug Registration and Regulatory Requirements in European Countries, World Journal of Pharmaceutical Research, 2018, Volume 7, Issue 16, 800-815.
16. Kumar B. Comparison of Regulatory Requirements for Generic Drugs Dossier in United States and Europe. Journal of Pharma Research. 2019; 8(8).